Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BABH study of intravenous bevacizumab for severe bleeding in hereditary hemorrhagic telangiectasia
2017-001031-39Phase 3Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in hereditary hemorrhagic telangiectasia (HHT), sponsored by Hospices Civils de Lyon. Started Jun 2020; status: completed.
02
Drugs
bevacizumab
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on 2017-001031-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001031-39.